Home / News / Army Researchers Subject MERS Vaccine Candidate to First Clinical Trial; Kayvon Modjarrad Comments

Army Researchers Subject MERS Vaccine Candidate to First Clinical Trial; Kayvon Modjarrad Comments

HealthU.S. Army scientists have launched a phase 1 clinical trial of an experimental vaccine against the Middle East respiratory syndrome coronavirus, DoD News reported Feb. 17.

Cheryl Pellerin writes researchers at the Walter Reed Army Institute of Research will administer the GLS-5300 vaccine in 75 trial participants at the institute’s clinical trial facility in Maryland.

Inovio Pharmaceuticals and GeneOne Life Science teamed up to develop the DNA vaccine candidate against MERS coronavirus.

“One of the benefits of a DNA vaccine is that you don’t need any kind of culture system, like eggs, and you can produce it very quickly,” said Kayvon Modjarrad, the trial’s lead investigator and associate director for the emerging infectious disease research program at WRAIR.

Modjarrad told DoD News that the vaccine candidate could be used by the Defense Department as a countermeasure in an effort to protect U.S. service personnel in the Middle East against the virus.

MERS is a severe respiratory condition that has infected over 1,600 individuals since its discovery in Saudi Arabia in 2012.

Check Also

Navy Eyes Single Combat System for Entire Surface Fleet

U.S. Navy officials are looking into developing a single combat system capable of operating on any kind of ship in the surface fleet to reduce the challenges in integrating ships and training service members, Defense News reported Monday. The Navy currently uses different combat systems on its destroyers, amphibious ships and carriers.

Leave a Reply

Your email address will not be published. Required fields are marked *